Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.

Conditions

Interventions

Lay summary

• To demonstrate the non-inferiority of GSK Biologicals’ MMRVR co-administered with HAV and PCV compared to ProQuad co-administered with HAV and PCV at Day 42 with respect to - the seroresponse rate for antibodies to -> varicella virus -> measles virus and rubella virus -> mumps virus - the geometric mean concentration (GMC) for anti-bodies to -> varicella virus -> hepatitis A virus in a subset of subjects -> S. pneumoniae serotypes (anti-PS) 4, 6B, 9V, 14, 18C, 19F and 23F in a subset of subjects • To demonstrate the non-inferiority of GSK Biologicals’ MMRVF co-administered with HAV and PCV compared to ProQuad co-administered with HAV and PCV at Day 42 with respect to - the seroresponse rate for antibodies to -> varicella virus -> measles virus and rubella virus -> mumps virus - GMC for antibodies to -> varicella virus -> hepatitis A virus in a subset of subjects -> anti-PS serotypes 4, 6B, 9V, 14, 18C, 19F and 23F in a subset of subjects

Documents

 

Publications

We have no "publications" for this trial. Help us by contributing data.

Registries